Anyone who is taking more than one drug is at risk of drug-drug interaction, an issue that occurs when drugs interfere with each other1. Drug-drug interactions can lead to potential issues with efficacy and/or toxicity and have been known to halt drug development. This is where Worldwide can help. Our experience conducting analysis for drug-drug interaction studies spans 3 decades.
Many of our scientists, analysts, and staff have more than 20 years of experience, enabling them to offer the best drug-drug interaction study design support. In addition, our history has enabled us to develop, validate, and utilize assays for the most common drugs assessed during drug-drug interaction studies. We can provide quick reliable results critical to determining your drug’s future.
PHARMACOGENOMICS: A CRITICAL COMPONENT TO YOUR DRUG DEVELOPMENT PROGRAM
Pharmacogenomics is another area which has the potential to impact the drug development process. An individual’s genetic make-up can interfere with the way they respond to or metabolize a drug. For example, some individuals may be poor metabolizers; while others may be rapid metabolizers. This can lead to potential issues with efficacy and/or toxicity. Worldwide knows this information can be critical to your development program.
WORLDWIDE CLINICAL TRIALS: SUPPORTING YOUR PATIENT POPULATION REQUIREMENTS
Worldwide has qualified assays to test for the most common genotypes. A substantial portion of our subject database has been voluntarily screened, saving you time and costs when recruiting special populations. A simple buccal swab is all that is needed to screen for a wide array of genotypes. Our current panel consists of the following and is continually growing.
Additionally, Worldwide uses validated Agena PGx assays. Based on the results, we can predict phenotypic expression and enzyme activity. Our pharmacogenomics laboratory equipment includes:
Make informed decisions, faster with Worldwide Clinical Trials’ Bioanalytical Laboratory